Met Life Investment Management, LLC Candel Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $18.1 Billion
- Q1 2025
A detailed history of Met Life Investment Management, LLC transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 15,227 shares of CADL stock, worth $96,995. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,227
Previous 13,773
10.56%
Holding current value
$96,995
Previous $119,000
27.73%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CADL
# of Institutions
85Shares Held
15.4MCall Options Held
536KPut Options Held
335K-
Baker Bros. Advisors LP New York, NY2.44MShares$15.5 Million0.16% of portfolio
-
Acorn Capital Advisors, LLC New York, NY2.15MShares$13.7 Million8.46% of portfolio
-
Northpond Ventures, LLC1.94MShares$12.3 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.74MShares$11.1 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA881KShares$5.61 Million0.41% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $184M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...